NASDAQ:ARVN Arvinas Q1 2024 Earnings Report $8.60 +0.95 (+12.42%) Closing price 04:00 PM EasternExtended Trading$8.56 -0.04 (-0.52%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Arvinas EPS ResultsActual EPS-$0.97Consensus EPS -$1.42Beat/MissBeat by +$0.45One Year Ago EPS-$1.54Arvinas Revenue ResultsActual Revenue$25.30 millionExpected Revenue$32.94 millionBeat/MissMissed by -$7.64 millionYoY Revenue Growth-22.20%Arvinas Announcement DetailsQuarterQ1 2024Date5/7/2024TimeBefore Market OpensConference Call DateTuesday, May 7, 2024Conference Call Time7:00AM ETUpcoming EarningsArvinas' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled on Monday, May 5, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Arvinas Earnings HeadlinesTruist Financial Lowers Arvinas (NASDAQ:ARVN) Price Target to $21.00April 12, 2025 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Roche Holding (OtherRHHBY) and Arvinas Holding Company (ARVN)April 9, 2025 | markets.businessinsider.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…April 17, 2025 | Paradigm Press (Ad)Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will TripleApril 9, 2025 | msn.comArvinas, Inc. (NASDAQ:ARVN) Receives $35.50 Average PT from BrokeragesApril 9, 2025 | americanbankingnews.comArvinas' (ARVN) "Buy" Rating Reaffirmed at HC WainwrightApril 9, 2025 | americanbankingnews.comSee More Arvinas Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arvinas? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arvinas and other key companies, straight to your email. Email Address About ArvinasArvinas (NASDAQ:ARVN), a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.View Arvinas ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth Ahead Upcoming Earnings HDFC Bank (4/18/2025)Intuitive Surgical (4/22/2025)Tesla (4/22/2025)Chubb (4/22/2025)Canadian National Railway (4/22/2025)Capital One Financial (4/22/2025)Danaher (4/22/2025)Elevance Health (4/22/2025)General Electric (4/22/2025)Lockheed Martin (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
